BOSTON, March 9 /PRNewswire/ -- ESBATech AG, a developer of fully-human antibody fragment therapeutics today announced that Dominik Escher, Ph.D., Chief Executive Officer, will present at the Sachs Associates 5th Annual North American Forum for Investing & Partnering in Biotech & Medtech.
Dr. Escher's presentation will take place March 13, 2006 at 4:10 P.M. at The Fairmont Copley Plaza Hotel in Boston, MA. Dr. Escher will be available for one-on-one meetings during the forum. His presentation will be available live via webcast and for replay at http://www.investorcalendar.com/CEPage.asp?ID=102439.
About ESBATech AG
Privately-held ESBATech is a Zurich, Switzerland based drug discovery and development company focused on advancing antibody-fragment therapeutics for inflammatory applications. Current venture investors include Novartis Venture Fund, BioMedinvest, Venture Incubator, BSI, Difasa, Network Capital and Management. The Company is currently raising additional venture financing in the US and Europe. ESBATech was founded in September 1998 and currently has 30 employees. For more information about ESBATech, please visit http://www.esbatech.com.
About Sachs Associates
Sachs Associates is a leading international forum for those interested in investing and partnering in the biotech and medtech industries. Going into its fifth year, the meeting attracts over 500 of the brightest players in the industry and provides prime executive-level networking and deal-making opportunities. The event features executive round-tables, presentations by mid-caps, small-caps, IPO prospects and venture-backed biotech and medtech companies.
For more information about Sachs Associates, visit http://www.sachsforum.com.
CONTACT: Bryan P. Murphy of LaVoie Group for ESBATech AG, +1-781-596-0200ext. 105, firstname.lastname@example.org